BRD4抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: NIH/3T3 cells, Primary antibody: P04654(BRD4 Antibody) at dilution 1/500, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 5 minutes    

  
  

Bromodomain-containing protein 4 (BRD4), a member of the BET (bromodomain and extraterminal) protein family, plays a critical role in epigenetic regulation by binding to acetylated lysine residues on histones. It facilitates transcriptional activation by recruiting transcriptional regulators, such as Mediator complex and P-TEFb, to chromatin, thereby influencing cell cycle progression, inflammation, and oncogene expression. Dysregulation of BRD4 is implicated in cancers, inflammatory diseases, and viral infections, making it a key therapeutic target.

BRD4 antibodies are essential tools for studying its expression, localization, and molecular interactions. These antibodies are widely used in techniques like Western blotting, immunoprecipitation, chromatin immunoprecipitation (ChIP), and immunofluorescence to investigate BRD4's role in chromatin remodeling, transcriptional elongation, and disease mechanisms. Specific monoclonal or polyclonal antibodies target distinct BRD4 domains (e.g., bromodomains, ET domain) to probe functional interactions or assess inhibitor binding in drug development studies. Validation of BRD4 antibodies is crucial due to potential cross-reactivity with other BET proteins (BRD2. BRD3. BRDT) and splice variants. Recent advances in selective BRD4 inhibitors (e.g., JQ1. OTX015) have further driven demand for reliable antibodies to evaluate target engagement and pharmacodynamic responses in preclinical models and clinical samples.